Table 1 Treatments for primary APL and... | American Society of Hematology

Table 1

Treatments for primary APL and for t-MN

Disease type/patient no.	At APL			Presence of myelodysplastic phase	At t-MN
Disease type/patient no.	Protocol*	VP-16 in consolidation therapy, mg/m²†	VP-16 in maintenance therapy, mg/m²‡	Presence of myelodysplastic phase	Therapy	Outcome
t-MN with progression to AML
10	APL92	500	480	+	Intensive chemotherapy	Died of disease progression
18	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
19	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
22	APL97	500	480	−	Intensive chemotherapy	Died of disease progression
48	APL97	500	480	+	Intensive chemotherapy	Alive in CR
79	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
83	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
108	APL97	500	0	+	Intensive chemotherapy then allogeneic stem cell transplantation	Died of disease progression
109	APL97	500	0	+	Intensive chemotherapy	Died of disease progression
t-MN without progression to AML (t-MDS-RCMD)
7	APL92	500	480	+	Supportive care	Alive without progression
49	APL97	500	480	+	Supportive care	Alive without progression

Disease type/patient no.	At APL			Presence of myelodysplastic phase	At t-MN
Disease type/patient no.	Protocol*	VP-16 in consolidation therapy, mg/m²†	VP-16 in maintenance therapy, mg/m²‡	Presence of myelodysplastic phase	Therapy	Outcome
t-MN with progression to AML
10	APL92	500	480	+	Intensive chemotherapy	Died of disease progression
18	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
19	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
22	APL97	500	480	−	Intensive chemotherapy	Died of disease progression
48	APL97	500	480	+	Intensive chemotherapy	Alive in CR
79	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
83	APL97	500	480	+	Intensive chemotherapy	Died of disease progression
108	APL97	500	0	+	Intensive chemotherapy then allogeneic stem cell transplantation	Died of disease progression
109	APL97	500	0	+	Intensive chemotherapy	Died of disease progression
t-MN without progression to AML (t-MDS-RCMD)
7	APL92	500	480	+	Supportive care	Alive without progression
49	APL97	500	480	+	Supportive care	Alive without progression

Two consecutive protocols (APL92⁴ or APL97⁵ of the Japan Adult Leukemia Study Group) were used.

A total of 100 mg/m² for 5 days.

A total of 80 mg/m² on days 1, 3, and 5 in the second and the sixth course.